Methotrexate with citrovorum factor rescue: reduced chemotherapy toxicity in the management of gestational trophoblastic neoplasms

Cancer. 1980 Feb;45(3):423-6. doi: 10.1002/1097-0142(19800201)45:3<423::aid-cncr2820450303>3.0.co;2-g.

Abstract

The comparative systemic toxicity of methotrexate (MTX) with citrovorum factor rescue (CF), MTX alone and actinomycin-D (Act-D) in the treatment of gestational trophoblastic neoplasms (GTN) was evaluated in the present study. Treatment with MTX-CF was associated with only a 4% incidence (1 of 25 patients) of hepatic and/or hematologic toxicity and total absence of either a generalized rash or marked alopecia. In contrast, both MTX alone and Act-D were associated with a 48% incidence (12 of 25 patients) of hepatic and/or hematologic toxicity. Actinomycin-D also induced a generalized rash and marked alopecia in 24% (6 of 25 patients) and 52% (13 of 25 patients) of the patients respectively. We found that MTX-CF is the least toxic single agent chemotherapeutic regimen in the management of GTN.

Publication types

  • Comparative Study

MeSH terms

  • Bone Marrow / drug effects
  • Dactinomycin / adverse effects
  • Drug Therapy, Combination
  • Female
  • Humans
  • Leucovorin / administration & dosage
  • Leucovorin / adverse effects*
  • Liver / drug effects
  • Methotrexate / administration & dosage
  • Methotrexate / adverse effects*
  • Pregnancy
  • Trophoblastic Neoplasms / drug therapy*
  • Uterine Neoplasms / drug therapy*

Substances

  • Dactinomycin
  • Leucovorin
  • Methotrexate